News | Atrial Fibrillation | May 08, 2020

PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints 

HRS late-breaking clinical trial shows low complication rates, 100 percent effective closure with next-generation stroke risk reduction technology

PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020

May 8, 2020 — Positive 12-month results were announced today from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation Boston Scientific Watchman FLX Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF). Presented as a late-breaking clinical trial at the Heart Rhythm Society (HRS) 2020 Science virtual meeting, the study evaluated performance of the Watchman FLX device as an alternative to oral anticoagulation therapy, including non-vitamin K antagonist oral anticoagulants (NOACs), for stroke risk reduction in patients with NVAF.

The prospective, non-randomized PINNACLE FLX trial included 400 patients in the U.S. with NVAF who were eligible for anti-coagulation therapy to reduce the risk of stroke but had an appropriate rationale to seek a non-pharmaceutical alternative. The trial met its primary safety endpoint – defined as occurrence of a major procedure-related complication within 7 days following the procedure or time of hospital discharge, whichever was later – with a low adverse event rate of 0.5 percent. The study also met its primary effectiveness endpoint, with data demonstrating a 100 percent rate of effective LAA closure at 12 months post-procedure with peri-device flow of less than 5 mm.

"We believe the next-generation Watchman FLX technology contributed to the excellent overall clinical performance seen in this study, notably the very low rate of safety events and high rate of effective closure," said Shephal Doshi, M.D., study co-principal investigator and cardiologist at Pacific Heart Institute at Providence St. John's Health Center, California. "In fact, we saw that 90 percent of patients showed absolutely no detectable leakage around the device at their 12-month follow up, which compares favorably to the rates of peri-device flow observed in the PROTECT-AF and PREVAIL trials with the predicate Watchman device and may translate into improved long-term clinical outcomes."

Data from the trial also demonstrated an implant success rate of 98.8 percent and that no patients experienced peri-procedural death, device embolization or pericardial effusion requiring cardiac surgery, all of which is favorable in the context of previous clinical studies.1 In addition, 96.2 percent of patients were able to discontinue oral anticoagulation following their 45-day follow up. Secondary endpoints from the PINNACLE FLX study, including the occurrence of ischemic stroke or systemic embolism, will be reported after 24 months of patient follow-up.

"As we have seen in previous clinical trials, Watchman technology is well-established as a safe and effective therapeutic option for patients with NVAF at increased risk for stroke and systemic embolism who need an alternative to a lifetime on anti-coagulant medications," said Ian Meredith, AM, global chief medical officer, Boston Scientific. "We are pleased with the performance exhibited by the next-generation Watchman FLX device in the PINNACLE FLX study, which mirrors positive European physician experience to date and underscores our commitment to advancing this technology for safe treatment of a broader population of eligible patients with NVAF." 

The next-generation Watchman FLX device received CE mark in March 2019 and is designed to advance procedural performance and safety while expanding the treatable population of patients with NVAF. The new frame allows for optimal device engagement with the tissue for long-term stability and a faster, complete seal of the LAA. Its fully rounded design also offers physicians the ability to safely enter, and maneuver within, the LAA and to fully recapture, reposition and redeploy the device during the procedure. The Watchman FLX device is available in broader size options to treat a wide range of patient anatomies.

The company plans to further evaluate the Watchman FLX device for patients with NVAF via continued enrollment in the ongoing OPTION trial – comparing the device to oral anticoagulants in patients who also undergo a cardiac ablation procedure – as well as in the CHAMPION-AF clinical trial, which will study a broader anticoagulant-eligible patient population to evaluate the device against NOACs for embolic stroke prevention. 

The Watchman FLX LAAC Device is an investigational device in the U.S. and not available for sale.

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

For more information: www.watchman.com

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...